Article
Development and validation of an LC-MS/MS method for simultaneous determination of SH-1028, an irreversible third-generation EGFR TKI, and two of its metabolites in human plasma: application in clinical pharmacokinetics.
Xenobiotica; the fate of foreign compounds in biological systems - 1 Feb 2023
Zhou Sufeng, Sha Bijun, Wang Lu, Zhao Yuqing, Wang Zhiqiang, Zhang Xian, Han Luwei, Shao Feng, Chen Xijing
Abstract excerpt
SH-1028 is a novel, potent, and highly selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) developed for the treatment of T790M Mutation-positive non-small cell lung cancer (NSCLC). The objective was to develop an LC-MS/MS method for the simultaneous determination of SH-1028 and its metabolites, Imp2 and Imp3, in human plasma.The plasma samples were extracted through protein...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.